- The complete response rate of liver metastasis in patients with metatstatic colorectal cancer treated with the systemic chemotherapy FOLFOX and cetuximab2013 | Publication without faculty affiliation
- Retention and response rates in 14 261 PsA patients starting TNF inhibitor treatment-results from 12 countries in EuroSpA2020 | First Faculty of Medicine
- Monotherapy with low-dose thalidomide for relapsed or refractory multiple myeloma: better response rate with earlier treatment2007 | Publication without faculty affiliation
- Monotherapy with low-dose thalidomide for relapsed or refractory multiple myeloma: better response rate with earlier treatment +12007 | Faculty of Medicine in Hradec Králové
- Monotherapy with low-dose thalidomide for relapsed or refractory multiple myeloma: better response rate with earlier treatment2007 | First Faculty of Medicine
- Real-world Six- and Twelve-Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients with Psoriatic Arthritis in Thirteen European Countries2022 | First Faculty of Medicine
- Efficacy of rituximab in primary immune thrombocytopenia: An analysis of adult pretreated patients from everyday hematological practice2012 | Faculty of Medicine in Hradec Králové, Central Library of Charles University, Third Faculty of Medicine
- Subcutaneous Bortezomib in Multiple Myeloma Patients Induces Similar Therapeutic Response Rates as Intravenous Application But It Does Not Reduce the Incidence of Peripheral Neuropathy2015 | Third Faculty of Medicine
- Decitabine improves response rate and prolongs progression-free survival in older patients with newly diagnosed acute myeloid leukemia and with monosomal karyotype: A subgroup analysis of the DACO-016 trial2018 | Central Library of Charles University, Faculty of Medicine in Pilsen
- Daratumumab with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients – real world evidence analysis2023 | Faculty of Medicine in Hradec Králové, Central Library of Charles University, First Faculty of Medicine
- A Randomized Controlled Trial of the Efficacy and Safety of CCX282-B, an Orally-Administered Blocker of Chemokine Receptor CCR9, for Patients with Crohn's Disease2013 | Publication without faculty affiliation
- 10 years of experience with thalidomide in multiple myeloma patients: Report of the Czech Myeloma Group2013 | Central Library of Charles University
- Longitudinal trends in blood pressure, prevalence, awareness, treatment, and control of hypertension in the Czech population. Are there any sex differences?2022 | First Faculty of Medicine, Faculty of Medicine in Pilsen
- Combined Therapeutic Modality with Rituximab, Fludarabin and Cyclophosphamide Followed by High Dose Therapy with Autologous Stem Cell Transplantation (ASCT) Leads to Excellent Response Rate and High Probability of Molecular Remission in Chronic Lymphocytic Leukemia (CLL) PatientsPublication without faculty affiliation
- Fertility-preserving treatment in women with endometrial cancer2016 | Third Faculty of Medicine
- Randomized Phase II Study of Bortezomib, Thalidomide, and Dexamethasone With or Without Cyclophosphamide As Induction Therapy in Previously Untreated Multiple Myeloma2013 | First Faculty of Medicine
- Certolizumab pegol plus MTX administered every 4 weeks is effective in patients with RA who are partial responders to MTX2012 | First Faculty of Medicine
- Pembrolizumab - another successfull therapy in the treatment of melanoma2016 | Third Faculty of Medicine
- Addition of rituximab significantly improves outcomes in patients with diffuse large B-cell lymphoma a single-center, retrospective study2007 | Faculty of Medicine in Hradec Králové
- European bio-naïve spondyloarthritis patients initiating TNF inhibitor: time trends in baseline characteristics, treatment retention and response2022 | First Faculty of Medicine
- Population and sample2019 | Faculty of Social Sciences
- Patient with lung metastases of malignant melanoma who have long-term survival in combination therapy BRAF and MEK inhibitors2019 | First Faculty of Medicine
- Dasatinib in imatinib-resistant or -intolerant CML patients: data from the clinical practice of 6 hematological centers in the Czech Republic2010 | First Faculty of Medicine
- Nivolumab in the treatment of metastatic melanoma2015 | Publication without faculty affiliation
- A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma2015 | First Faculty of Medicine
- Patient with abrain metastases of malignant melanoma a long-term surviving with BRAF and MEK inhibitor in combination therapy2018 | First Faculty of Medicine
- An ocular lesion of unknown aetiology2021 | First Faculty of Medicine
- Treatment of anaemia with erythropoiesis-stimulating proteins in patients with myelodysplastic syndrome2010 | First Faculty of Medicine
- Treatment of anaemia with erythropoiesis-stimulating proteins in patients with myelodysplastic syndrome2010 | Publication without faculty affiliation